Case report: ALK-positive histiocytosis presented as bilateral synchronous breast masses with long-term remission on crizotinib

被引:1
作者
Zhou, Yuhang [1 ]
Hurtado-Castillo, Marisabel [1 ]
Pandey, Om [1 ]
机构
[1] Univ Texas Austin, Dept Oncol, Austin, TX 78712 USA
关键词
ALK1; histiocytosis; breast; brain; crizotinib; CELL; RESISTANCE; INVOLVEMENT; MECHANISMS; MUTATION; GROWTH;
D O I
10.3389/fmed.2023.1288849
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
ALK-positive histiocytosis (APH) is a rare type of histiocytic neoplasm with characteristic ALK (Anaplastic Lymphoma Kinase) gene translocation and fusion, with only 27 reported cases in the literature. In this study, we report the first case of synchronous bilateral breast involvement of ALK-positive histiocytosis on initial presentation in a 46-year-old Hispanic woman. APH was diagnosed by the confirmation of clonal histiocyte proliferation with ALK overexpression on IHC and the presence of KIF5B-ALK gene fusion from her breast and lung biopsies. The patient in our study is currently under complete and long-term remission with crizotinib treatment (an ALK inhibitor). This report expands on the clinical manifestation of APH, emphasizes the importance of ALK detection in histiocytic diseases, and provides the efficacy and long-term prognosis of the ALK inhibitor therapy for APH.
引用
收藏
页数:7
相关论文
共 43 条
  • [41] Long-Term Survival of Over 6 Years with Afatinib Sequential Treatment in a Patient with EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Case Report
    Tu, Hai-Yan
    Li, Yang-Si
    Yang, Jin-Ji
    Chen, Hua-Jun
    Jiang, Ben-Yuan
    Zhong, Wen-Zhao
    Yang, Xue-Ning
    Wu, Yi-Long
    CLINICAL DRUG INVESTIGATION, 2021, 41 (05) : 483 - 488
  • [42] Long-term progression-free survival in HR+/HER2+advanced breast cancer with combination therapy with a CDK4/6 inhibitor and first-line maintenance therapy: A case report
    Cai, Yihong
    Zhang, Jinling
    Duan, Hongxia
    Liu, Fan
    ONCOLOGY LETTERS, 2025, 29 (05)
  • [43] Long-Term Molecular Remission Achieved by Antibody Anti-CD22 and Ponatinib in a Patient Affected by Ph' plus Acute Lymphoblastic Leukemia Relapsed after Second Allogeneic Hematopoietic Stem Cell Transplantation: A Case Report
    Pirosa, Maria Cristina
    Leotta, Salvatore
    Cupri, Alessandra
    Stella, Stefania
    Martino, Enrica Antonia
    Scalise, Luca
    Sapienza, Giuseppe
    Calafiore, Valeria
    Mauro, Elisa
    Spadaro, Andrea
    Vigneri, Paolo
    Di Raimondo, Francesco
    Milone, Giuseppe
    CHEMOTHERAPY, 2018, 63 (04) : 220 - 224